A New Frontier in Autoimmune Research At the 62nd EASD Annual Meeting, Mozart Therapeutics took center stage to share critical updates regarding their lead therapeutic candidate, MTX-101. This presentation marks an important milestone for the company as they continue to investigate novel ways to treat autoimmune diseases, specifically focusing on Type 1 Diabetes (T1D). Understanding…